SAT-3153

About Satellos Bioscience

Satellos Bioscience is a clinical-stage biotechnology company with a mission to develop disease-modifying treatments for degenerative muscle conditions by addressing a fundamental biological flaw in muscle regeneration. The company's key achievement is the discovery of a polarity defect in muscle stem cells (satellite cells) in dystrophic muscle, which forms the basis of its proprietary drug discovery platform. Its strategy is to advance small molecule correctors of this defect, with a lead program targeting Duchenne muscular dystrophy (DMD), aiming to shift the therapeutic paradigm from managing symptoms to enabling functional repair. Operating as a public company on the TSX Venture Exchange, Satellos represents a high-science, high-potential investment in an area of severe unmet need.

Therapeutic Areas

Other Duchenne Muscular Dystrophy (DMD) Drugs